Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%

Technology brief from Ars Technica.

From the source

Markers released top-line results today after previously reporting the trial succeeded.

Why it is on APerez.net

This is part of the broader technology stream: useful context for hardware, software, infrastructure, and the tools that shape hands-on technical work.

This APerez.net Wire Brief is an automatically created digest from an RSS item. It does not republish the full source article.